Companies · Other

ABK Biomedical Inc

HALIFAX · Other

Diligence memoA one-page analyst read on ABK Biomedical Inc — recommendation, valuation, rhythm, risks.
$80.7M
Total raised · real
4
Rounds
0.1×
Latest step-up
Top 6%
Sector rank · raised
Series B
Latest stage · inferred · Tue Oct 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

ABK Biomedical Inc looks under-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.14× the median modeled value of Series B Other companies in 2025–2027 (207 peers) — value vs value, same stage and era.
Active
  • Last raise 9 mo ago; this sector typically re-raises about every 11 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other

ABK Biomedical Inc is one of 25015 Other companies tracked from HALIFAX. By capital raised it ranks among the largest (ahead of 95% of sector peers), and mid-pack by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
6
Investors (latest)
2025-10-14
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries B · 2019-04-08 Raised $23M (real) Modeled valuation $390M (est)$23M$390MSeries B2019Series B · 2022-09-09 Raised $18M (real) Modeled valuation $175M (est)$18M$175MSeries B2022Series B · 2022-12-05 Raised $28M (real) Modeled valuation $260M (est)$28M$260MSeries B2022Series B · 2025-04-29 Raised $26M (real) Modeled valuation $132M (est)$26M$132MSeries B2025Series B · 2025-10-14 Raised $2.6M (real) Modeled valuation $12M (est)$2.6M$12MSeries B2025+$18M+$28M+$26M+$2.6MCumulative $99M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$23.5M · 2019
Series B extension$18.1M · 2022
Series B extension$28.5M · 2022
Series B extension$26.1M · 2025
Series B extension$2.6M · 2025

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.

Modeled valuation trajectory
$11.5M
Base estimate est.
$6.4M
Conservative case
$16.1M
Upside case
$14.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Series B · modeled $390.4M · 2019-04-082019Series B · modeled $175.1M · 2022-09-09Series B · modeled $260.1M · 2022-12-05Series B · modeled $131.7M · 2025-04-29Series B · modeled $11.5M · 2025-10-142025
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
68%
Survival probability
45% low · 83% high
1.28×/yr
Annual markup
1.55×/yr upside case
0.7 yr
Elapsed time used
0.7 yr actual, capped for stale marks
general
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
20 mo
Avg between rounds
$12.4M/yr
Capital velocity
7.2 yr
On record since
2019
First round
5
Rounds on file
How it compares to the market

Benchmarked against 25015 companies in Other. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 39× above median
This company$80.7M
Sector median$2.0M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.1× of median
This company$2.6M
Sector median$19.6M
Modeled value — vs sector median (estimate, all stages) 0.7× of median
This company$11.5M
Sector median$17.7M

Raised more than 95% of sector peers (real $). Modeled value above 40% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #188 of 207.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)Acorn Sim Investor Holdings, LLC · Series B Raised $38.6M · modeled $204.0M (est)Aircapture, Inc. · Series B Raised $40.0M · modeled $197.5M (est)Bathhouse Holdings Inc. · Series B Raised $34.4M · modeled $178.0M (est)Chlorum Solutions USA LLC · Series B Raised $35.4M · modeled $176.0M (est)Olympus Pines LLC · Series B Raised $35.0M · modeled $175.5M (est)Fraser Topco LLC · Series B Raised $32.8M · modeled $175.4M (est)Ketryx Corp · Series B Raised $54.2M · modeled $172.7M (est)r.Potential Inc. · Series B Raised $33.0M · modeled $170.5M (est)Helper Bees, Inc. · Series B Raised $58.7M · modeled $169.5M (est)Kingsland Pointe Holdings, LLC · Series B Raised $33.1M · modeled $168.7M (est)Modern Life Group Inc. · Series B Raised $34.7M · modeled $168.0M (est)BR MMJ Acquisition Co LLC · Series B Raised $37.5M · modeled $167.9M (est)ABK Biomedical Inc (this company) Raised $80.7M · modeled $11.5M (est)ABK Biomedical Inc
CompanyStageRaised · realValue · estvs peer med.
Acorn Sim Investor Holdings, LLCSeries B$38.6M$204.0M2.40×
Aircapture, Inc.Series B$40.0M$197.5M2.33×
Bathhouse Holdings Inc.Series B$34.4M$178.0M2.10×
Chlorum Solutions USA LLCSeries B$35.4M$176.0M2.07×
Olympus Pines LLCSeries B$35.0M$175.5M2.07×
Fraser Topco LLCSeries B$32.8M$175.4M2.06×
Ketryx CorpSeries B$54.2M$172.7M2.03×
r.Potential Inc.Series B$33.0M$170.5M2.01×
Helper Bees, Inc.Series B$58.7M$169.5M2.00×
Kingsland Pointe Holdings, LLCSeries B$33.1M$168.7M1.99×
Modern Life Group Inc.Series B$34.7M$168.0M1.98×
BR MMJ Acquisition Co LLCSeries B$37.5M$167.9M1.98×
ABK Biomedical Inc this companySeries B$80.7M$11.5M0.14×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$23.5M2019-04-08$130.6M$390.4M90%
Series B$18.1M2022-09-09$100.5M$175.1M90%
Series B$28.5M2022-12-05$158.3M$260.1M90%
Series B$26.1M2025-04-29$145.0M$131.7M90%
Series B$2.6M2025-10-14$14.2M$11.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$23.5M2019-04-08
    • First recorded raise — entered as Series B.
    • 10 investors on this round.
  2. Series B$18.1M2022-09-09
    • Raised again after 41 mo — slower than the ~11 mo sector norm.
    • Round 1.3× smaller than the prior — bridge or down round.
    • 16 investors on this round.
  3. Series B$28.5M2022-12-05
    • Came back fast: 3 mo vs the ~11 mo sector norm.
    • Round 1.6× larger than the prior — scaling up.
    • 23 investors on this round.
  4. Series B$26.1M2025-04-29
    • Raised again after 29 mo — slower than the ~11 mo sector norm.
    • Round roughly the size of the prior one.
    • 24 investors on this round.
  5. Series B$2.6M2025-10-14
    • Came back fast: 6 mo vs the ~11 mo sector norm.
    • Round 10.2× smaller than the prior — bridge or down round.
    • 6 investors on this round.
Intelligence
2027 ~Q2
Modeled next raise · ~20mo cadence
$2.6M
Modeled next size est.range $2.6M$4.1M
0.1×
Last step-up
$12.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Ketan Patel9 other2022-09
Robert Orr6 other2019-04
Aaron Berez3 other2019-04
James McLaren1 other2019-04
Michael Mangano1 other2019-04
Michael Tyson1 other2019-04
Anthony Headley2022-09
Aravind Arepally2022-09
Bob Abraham2019-04
Carissa Bellardine Black2025-04
Carissa Black2022-12
David Dobrowski2019-04
David Dobrowsky2022-09
Gary Donofrio2019-04
James Bellardine Eadie2025-04
James Bellardine McLaren2025-04
Joseph Bellardine Siletto2025-04
Keten Patel2025-04
Lucy Bellardine Bataneant2025-04
Marc Gregoire2019-04
Mike Tyson2022-09
Registry & provenance

ABK Biomedical Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1773773
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Analytics for Life, Inc.Software / TechSeries B$65.1M$2.6Mnetwork2 shared operators · same stage
Ivenix, Inc.BiotechnologySeries B$82.9M$396.9Mnetwork1 shared operator · same stage
Reshape Medical, Inc.BiotechnologySeries B$75.1M$436.6Mnetwork1 shared operator · same stage
Baja Aquaculture, Inc.OtherSeries A$18.6M$80.8Mnetwork1 shared operator · same sector
INTELLEFLEX CorpOtherSeries A$14.9M$88.7Mnetwork1 shared operator · same sector
Aquesys IncBiotechnologySeries B$49.5M$1.2Bnetwork1 shared operator · same stage
NFlection Therapeutics, Inc.BiotechnologySeries B$44.0M$43.6Mnetwork1 shared operator · same stage
Roll Rite Group Holdings LlcOtherSeries B$19.7M$11.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Akeso Biomedical, Inc.OtherSeries A$7.3M84%
ABT Holdings, Inc.OtherSeries A$30.3M83%
Abreos Biosciences, Inc.Biotech / PharmaSeries A$172.7M83%
BioTork LLCOtherSeed$45.2M83%
Awakn Life Sciences Inc.OtherSeed$21.5M82%
ABL BIO USA, Inc.BiotechnologySeed$24.4M82%
AbX Biologics, Inc.Biotech / PharmaPre-Seed$51.2M82%
Bakpax Inc.OtherSeed$55.8M81%
Frequently asked
How much funding has ABK Biomedical Inc raised?
ABK Biomedical Inc has raised approximately $80.7M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is ABK Biomedical Inc's estimated valuation?
Provath's modeled valuation for ABK Biomedical Inc is approximately $11.5M (modeled range $6.4M–$16.1M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is ABK Biomedical Inc at?
ABK Biomedical Inc's latest modeled financing stage is Series B. Its most recent recorded round closed around Tue Oct 14.
What does ABK Biomedical Inc do and where is it based?
ABK Biomedical Inc operates in the Other sector, based in HALIFAX.
Explore related

See where ABK Biomedical Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at ABK Biomedical Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.